Bienvenue sur le forum TechNet

WHO/Europe is working with immunization programmes across the European Region to help them raise awareness about HPV vaccination, address obstacles to high uptake and prepare for HPV vaccine introduction where it is not yet part of the routine immunization programme. As part of this work ...

HLN today released a new version of its ICE Open Source Immunization Evaluation and Forecasting software covering the following changes: HPV updates: (1) Added support for new 2-dose series; recommend based on 2- or 3-dose series accordingly. (2) Ignore (HPV, bivalent (Cervarix)) shots administer...

by Osman Mansoor, UNICEF, and Debra Kristensen, PATH As newer vaccines are introduced in low-income countries, immunization programs are facing difficult challenges related to proper storage, transport, tracking, and delivery of vaccines. While some of these challenges are not new, the importance o...

The Indian government suspended research in April 2010 on the feasibility and safety of human papillomavirus (HPV) vaccine in two Indian states (Andhra Pradesh and Gujarat) amid public concerns about its safety. This paper describes cervical cancer and cancer surveillance in India and reviews the ep...

The American Academy of Pediatrics (AAP) recommends that the HPV vaccine be administered at 11 to 12 years of age in both boys and girls.I do not know the studies that show cost-benefit analysis of the vaccine in females, especially in a scenario when many countries are against this vaccine. The ...

In collaboration with Merck & Co., Inc. and GSK, PATH Seattle has prepared a list of countries where each of these company's vaccines is licensed and a world map showing the countries where one of the vaccines is licensed for use and the countries where both vaccines are licensed for use. These ...

This message has been cross-posted from HPV Vaccine Global Community of Practice. With many thanks to Robert Steinglass. Dear Lisa, I agree with Sarah Mullins that there is a great opportunity to find links with a larger package of interventions, including tetanus vaccination. The following four r...

Webinar now available on Cervical Cancer Action website; Please visit the Cervical Cancer Action Multimedia web page to watch and listen. For more information, please contact [email protected] [size=14]HPV vaccination in developing countries: Recent lessons from six pilot programs[/si...

Written by: S Kibet, WHO Kenya; P Zaninka & T Rweizire, Uganda EPI; R Anderson, UW; and S Newland, PATH Improving the efficiency and effectiveness of vaccine supply chains is no easy task, especially when data is difficult to gather, financing is tight, and there is pressure to improve and ex...

Optimizing presentation and packaging for HPV vaccinesby Debbie Kristensen and D. Scott LaMontagne, PATH Working in collaboration with the Vaccine Presentation and Packaging Advisory Group (VPPAG), representatives from the public health community have initiated a series of studies to guide presentat...

Temperature Monitoring Study To Commence in Vietnam and Uganda by Joanie Robertson, Huong Vu and James Cheyne, PATH While some vaccines will lose their potency if they are stored at temperatures above or below the standard 2° to 8°C, many vaccines are quite heat stable and can tolerate temperatures...

Public Sector and Industry: Working Together to Better Meet Developing Country Needsby Debra D. Kristensen, Senior Technical Officer and Policy Advisor, PATH, and Christopher B. Nelson, Senior Director, Medical Affairs and Policy, Merck & Co, Inc. Originally established in 2007 by the GAVI Allia...

POST 01384E: EXPERIENCES OF INTRODUCING HPV 5 FEBRUARY 2009 ****************************************** Can anyone share their experience of introducing HPV in their countries? Especially those in the SEARO Region. Thanks Karma Tshering ([email protected]) Ministry of Health, Bhutan Post ...

POST 01384E: EXPERIENCES OF INTRODUCING HPV 5 FEBRUARY 2009 ****************************************** Can anyone share their experience of introducing HPV in their countries? Especially those in the SEARO Region. Thanks Karma Tshering ([email protected]) Ministry of Health, Bhutan Post ...

POST 01385E: EXPERIENCES OF INTRODUCING HPV VACCINE 5 FEBRUARY 2009 ****************************************** Inadvertently omitted 'vaccine' from the post title, therefore reposting the contribution. No intention of encouraging bio-terrorism. Entirely an error of omission. Many apologies. Ca...

POST 01385E: EXPERIENCES OF INTRODUCING HPV VACCINE 5 FEBRUARY 2009 ****************************************** Inadvertently omitted 'vaccine' from the post title, therefore reposting the contribution. No intention of encouraging bio-terrorism. Entirely an error of omission. Many apologies. Ca...

POST 01237E: Human Papillomavirus update 8 MARCH 2008 ******************************************* Cervical cancer has a devastating impact on women’s health around the world. Approximately, 500.000 women develop cervical cancer every year, and half of them do not survive it. Almost 80% of these ...

POST 01137E : CERVICAL CANCER PREVENTION 9 August 2007 The following new materials especially on cervical cancer prevention and HPV vaccine are sent to you by : Scott_Wittet, Advocacy and Communication, Cervical Cancer Vaccine Project, PATH This message is sent in the "forward" mode to preserve...

The introduction of HPV vaccination is facing many challenges. The article published by Pollack et al. in the January issue of the Bulletin of the World Health Organization, besides providing useful information about the disease and the vaccine, discusses these challenges. Possible integration int...